Alzheimer's pill advances to final phase of human trials
Framingham biotechnology firm Alzheon Inc. announced Monday that in 2017 it will begin registering patients for the final phase of human trials for of a pill to treat Alzheimer’s disease.
The company’s recent studies provided the final clinical data necessary to move into phase 3 in the human study, according to Alzheon. This is the final phase of human trials before a company can apply for Federal Drug Administration approval to bring the drug to market. So far, results from a study of the medicine ALZ-801 focused on the effectiveness and safety of the pill format of the drug, finding reduced instances of vomiting and steady levels of drug delivery with low variance among the subjects.
The company will present the results at the Alzheimer’s Association International Conference this week in Toronto.
The company will also present its results of two previous studies with more than 2,000 patients that examined the active compound in the tablet, tramiprosate, which was found to have benefits on cognitive and functional levels for those with mild to moderate Alzheimer’s and a gene linked to the disease.
WBJ Web Partners
Most Recent
Most Recent
0 Comments